Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

CORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW R&D COMPANY (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion Share as Stock Dividend Actelion R&D Unit to Spin Out into Standalone Company Based and Listed in Switzerland; New R&D Company to Continue Actelion's Successful Culture of Innovation and Johnson & Johnson to Hold Substantial Minority Interest Acquisition Expected to Accelerate Johnson & Johnson Revenue and Earnings Growth Rates; Immediately...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>